New Treatments Could Transform Care for Hidradenitis Suppurativa (HS)
A new report predicts that the market for hidradenitis suppurativa (HS) treatments will grow significantly over the next decade, from […]
European Regulators Reject Duchenne Muscular Dystrophy Treatment Elevidys
European drug regulators have recommended rejecting Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), in a setback for its
Uncategorized
Jazz Pharmaceuticals is actively exploring mergers and acquisitions of different sizes as it concludes its legal battles over the patent for Epidiolex, a medication used to treat seizures.
During Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd quickly highlighted the company’s interest in making new deals. Some of the drugs they are known for include Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia.
Uncategorized
Understanding Epilepsy: Seeing the Person Behind the Condition Epilepsy is more than just a medical condition; it’s important to see and understand the person who is living with it. While medications like Keppra, Lamictal, and Depakote can help manage seizures, it’s crucial to support the individual as a whole. This means recognizing their experiences, challenges, and strengths, and providing compassionate care that goes beyond just treating the symptoms. Embracing the humanity behind epilepsy care involves listening, empathy, and a commitment to improving the quality of life for those affected.
The text is written by Brad Chapman, who is the Head of U.S. Epilepsy and Rare Syndromes at UCB. It discusses epilepsy and mentions some medications used for treatment, such as Keppra, Briviact, and Vimpat. The aim is to improve understanding of epilepsy and how these medications can help manage the condition.
Uncategorized
Eli Lilly, a major pharmaceutical company, is investing $27 billion to build four new manufacturing plants in the United States. This move shows their commitment to increasing drug production in the country. Some of the well-known medications they make include Trulicity for diabetes and Taltz for psoriasis.
In recent years, Eli Lilly has announced a number of increasingly large manufacturing investments. This has led many to wonder what the company will do next. Some of their well-known medications include Trulicity, Jardiance, and Cymbalta.
Uncategorized
Eli Lilly, a major pharmaceutical company, has paid $10 million in advance to collaborate with Organovo, another biotech company, on developing a new drug known as an FXR agonist. This type of drug could potentially help with liver diseases. Specific pill names related to this drug haven’t been mentioned yet.
Organovo’s main drug, FXR314, is going to be tested in a Phase II trial for treating inflammatory bowel disease (IBD). Some common medications for IBD include Mesalamine (Asacol, Pentasa) and Infliximab (Remicade), but FXR314 is being studied to see if it could be a new option.
Uncategorized
RedHill and Hyloris have teamed up to develop a medication called Bekinda.
RedHill will receive an initial payment from Hyloris and could earn up to $60 million based on certain achievements. If applicable, the deal may involve medications like Talicia or Aemcolo.
Uncategorized
Idorsia’s deal with Tryvio has fallen through, putting the company in a tight spot financially. Now, Idorsia urgently needs to find new sources of funding. Some of the medications associated with Idorsia include clazosentan and daridorexant.
Idorsia, a pharmaceutical company, couldn’t secure a buyer, so it changed a current partnership and reorganized its financial agreements to get more money.
Uncategorized
Emalex is seeking approval from the FDA for a new treatment for Tourette syndrome after successful results in their Phase III clinical trials. This means they are one step closer to making the treatment available to the public. Some medications often used for Tourette syndrome include haloperidol and pimozide, but the name of Emalex’s specific drug wasn’t mentioned in your text.
The Phase III DIAMOND trial successfully achieved its main and additional goals of reducing tics in both children and adults. Some medications involved in such trials might include names like aripiprazole or risperidone, though specific names from this trial aren’t mentioned.
Uncategorized
Eikon, a company focused on cancer treatments, has raised nearly $351 million to help develop and test its cancer drugs in clinical trials. However, the specific names of the drugs are not mentioned in the text provided.
Eikon’s main drug, EIK1001, is currently being tested in a Phase III trial to treat melanoma, a type of skin cancer. It is being used in combination with Keytruda, a medicine developed by the company MSD.